Moreover, a 2008 review [9] assessed the clinical equivalence of generic and branded drugs in cardiovascular disease, by evaluating 47 papers published in recent literature on nine subclasses of cardiovascular drugs (betablockers, ACE-inhibitors, calcium antagonists, antiplatelet drugs, and statins), most of which (81%) were randomized and controlled clinical studies. Here, ACE is linked to cardiovascular disorder.